» Articles » PMID: 11520893

Transfection-enforced Bcl-2 Overexpression and an Anti-Parkinson Drug, Rasagiline, Prevent Nuclear Accumulation of Glyceraldehyde-3-phosphate Dehydrogenase Induced by an Endogenous Dopaminergic Neurotoxin, N-methyl(R)salsolinol

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2001 Aug 25
PMID 11520893
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, was found to induce apoptosis in human dopaminergic SH-SY5Y cells by step-wise activation of apoptotic cascade; collapse in mitochondrial membrane potential, DeltaPsim, activation of caspases, and fragmentation of DNA. Recently, accumulation of gylceraldehyde-3-phosphate dehydrogenase (GAPDH) in nuclei was proposed to play an important role in apoptosis. In this paper, involvement of GAPDH in apoptosis induced by N-methyl(R)salsolinol was studied. The isoquinoline reduced DeltaPsim within 3 h, as detected by a fluorescence indicator, JC-1, then after 16 h incubation, GAPDH accumulated in nuclei by detection with immunostaining. To clarify the role of GAPDH in apoptotic process, a stable cell line of Bcl-2 overexpressed SH-SY5Y cells was established. Overexpression of Bcl-2 prevented the decline in DeltaPsim and also apoptotic DNA damage induced by N-methyl(R)salsolinol. In Bcl-2 transfected cells, nuclear translocation of GAPDH was also completely suppressed. In addition, a novel antiparkinsonian drug, rasagiline, prevented nuclear accumulation of GAPDH induced by N-methyl(R)salsolinol in control cells. These results suggest that GAPDH may accumulate in nuclei as a consequence of signal transduction, which is antagonized by anti-apoptotic Bcl-2 protein family and rasagiline. The results are discussed in concern to intracellular mechanism underlying anti-apoptotic function of rasagiline analogues.

Citing Articles

Rasagiline Exerts Neuroprotection towards Oxygen-Glucose-Deprivation/Reoxygenation-Induced GAPDH-Mediated Cell Death by Activating Akt/Nrf2 Signaling.

Lecht S, Lahiani A, Klazas M, Naamneh M, Rubin L, Dong J Biomedicines. 2024; 12(7).

PMID: 39062165 PMC: 11275171. DOI: 10.3390/biomedicines12071592.


Personalized, Precision Medicine to Cure Alzheimer's Dementia: Approach #1.

Fessel J Int J Mol Sci. 2024; 25(7).

PMID: 38612719 PMC: 11012190. DOI: 10.3390/ijms25073909.


Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis.

Cunha-Oliveira T, Montezinho L, Simoes R, Carvalho M, Ferreiro E, Silva F Cells. 2024; 13(3.

PMID: 38334639 PMC: 10854804. DOI: 10.3390/cells13030248.


In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.

Schuster J, Dreyhaupt J, Monkemoller K, Dupuis L, Dieterle S, Weishaupt J Eur J Neurol. 2024; 31(4):e16204.

PMID: 38240416 PMC: 11235627. DOI: 10.1111/ene.16204.


Application of OpenArray Technology to Assess Changes in the Expression of Functionally Significant Genes in the Substantia Nigra of Mice in a Model of Parkinson's Disease.

Troshev D, Kolacheva A, Pavlova E, Blokhin V, Ugrumov M Genes (Basel). 2023; 14(12).

PMID: 38137024 PMC: 10742853. DOI: 10.3390/genes14122202.